Rigel Pharmaceuticals (RIGL) investor relations material

Executive summary

• Achieved total revenues of $58.8 million in Q1 2026, with net product sales of $54.9 million, up 26% year-over-year, driven by TAVALISSE, GAVRETO, and REZLIDHIA.

• Maintained profitability with Q1 2026 net income of $8.7 million, though down from $11.4 million in Q1 2025 due to higher R&D and SG&A expenses.

• Commercial portfolio expanded to three products across four indications, reflecting successful execution of a multi-year growth strategy and global market penetration.

• Advanced clinical pipeline, including ongoing Phase 1b study of R289 for lower-risk MDS, with data expected by year-end 2026.

• Company maintains a solid financial foundation, ending Q1 with $146.7 million in cash, cash equivalents, and short-term investments.

Financial highlights

• Q1 2026 net product sales: $54.9 million (TAVALISSE $37.3 million, GAVRETO $9.6 million, REZLIDHIA $8.0 million), up 26% year-over-year.

• Total Q1 revenue: $58.8 million, including $3.9 million from collaborations and contract revenues.

• Net income for Q1: $8.7 million ($0.47 basic, $0.44 diluted EPS).

• Cash, equivalents, and short-term investments at quarter-end: $146.7 million.

• Total costs and expenses: $46.9 million, up from $40.6 million in Q1 2025, mainly due to R&D and commercial expansion.

Outlook and guidance

• 2026 revenue guidance maintained at $275–$290 million, with net product sales of $255–$265 million and contract revenues of $20–$25 million.

• Positive net income expected for full year 2026 while funding clinical development.

• R289 Phase 1b dose expansion data expected by end of 2026; potential registration study in 2027.

• Management expects product sales to increase as reimbursement headwinds ease and commercial execution continues.

• Existing cash and investments expected to fund operations for at least the next 12 months.